Physician profile
Mark John Mendolla
NPI 1679559199
$4,405.79
in general payments reported to CMS, 2019-2025
22 companies · $254 in 2025
The $254 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $183 · 2021: $901 · 2022: $388 · 2023: $1,272 · 2024: $701 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,226.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,767.70 | 2019-2024 | Xarelto |
| Medtronic, INC. | $482.03 | 2021-2023 | Azure Xt Dr Mri Surescan, Micra |
| Abbott Laboratories | $305.69 | 2021-2023 | Amplatzer Amulet |
| E.R. Squibb & Sons, L.L.C. | $228.37 | 2019-2023 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.64 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $213.38 | 2019-2022 | |
| Pfizer INC. | $171.16 | 2019-2021 | |
| Medtronic Vascular, INC. | $148.06 | 2019 | |
| Shockwave Medical, INC | $128.94 | 2025 | |
| Amarin Pharma, INC. | $122.93 | 2019-2021 | |
| Boston Scientific Corporation | $120.86 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals Lp | $114.46 | 2019-2023 | Farxiga |
| Cvrx, INC. | $90.82 | 2024-2025 | Barostim Neo System |
| Cardiva Medical, INC. | $68.45 | 2023 | Cardiva Vascade 6/7f Vcs |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.64 | 2021-2023 | Lifevest |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $43.85 | 2019 | |
| Amgen INC. | $39.88 | 2021-2023 | Repatha |
| Sanofi-Aventis U.S. LLC | $22.15 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.99 | 2019 | |
| Glaxosmithkline, LLC. | $14.41 | 2019 | |
| Amryt Pharma Holdings Ltd | $13.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mendolla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.